Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus

Dan P Christensen; Mattias Salling Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen

doi:10.2119/molmed.2011.00021

Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus

Dan P Christensen, Mattias Salling Dahllöf, Morten Lundh, Daniel N Rasmussen, Mette D Nielsen, Nils Billestrup, Lars G Grunnet, Thomas Mandrup-Poulsen

Endocrinology and Metabolism

167 Citations (Scopus)

Abstract

Both common forms of diabetes have an inflammatory pathogenesis in which immune and metabolic factors converge on interleukin-1β as a key mediator of insulin resistance and β-cell failure. In addition to improving insulin resistance and preventing β-cell inflammatory damage, there is evidence of genetic association between diabetes and histone deacetylases (HDACs); and HDAC inhibitors (HDACi) promote β-cell development, proliferation, differentiation and function and positively affect late diabetic microvascular complications. Here we review this evidence and propose that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes.

Original language	English
Journal	Molecular Medicine
Volume	17
Issue number	5-6
Pages (from-to)	378-90
Number of pages	13
ISSN	1076-1551
DOIs	https://doi.org/10.2119/molmed.2011.00021
Publication status	Published - May 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2119/molmed.2011.00021

Cite this

@article{918185e7d28640df8e3e1a7870e6d5d2,

title = "Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus",

abstract = "Both common forms of diabetes have an inflammatory pathogenesis in which immune and metabolic factors converge on interleukin-1β as a key mediator of insulin resistance and β-cell failure. In addition to improving insulin resistance and preventing β-cell inflammatory damage, there is evidence of genetic association between diabetes and histone deacetylases (HDACs); and HDAC inhibitors (HDACi) promote β-cell development, proliferation, differentiation and function and positively affect late diabetic microvascular complications. Here we review this evidence and propose that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes.",

author = "Christensen, {Dan P} and Dahll{\"o}f, {Mattias Salling} and Morten Lundh and Rasmussen, {Daniel N} and Nielsen, {Mette D} and Nils Billestrup and Grunnet, {Lars G} and Thomas Mandrup-Poulsen",

year = "2011",

month = may,

doi = "10.2119/molmed.2011.00021",

language = "English",

volume = "17",

pages = "378--90",

journal = "Molecular Medicine",

issn = "1076-1551",

publisher = "BioMed Central",

number = "5-6",

}

TY - JOUR

T1 - Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus

AU - Christensen, Dan P

AU - Dahllöf, Mattias Salling

AU - Lundh, Morten

AU - Rasmussen, Daniel N

AU - Nielsen, Mette D

AU - Billestrup, Nils

AU - Grunnet, Lars G

AU - Mandrup-Poulsen, Thomas

PY - 2011/5

Y1 - 2011/5

N2 - Both common forms of diabetes have an inflammatory pathogenesis in which immune and metabolic factors converge on interleukin-1β as a key mediator of insulin resistance and β-cell failure. In addition to improving insulin resistance and preventing β-cell inflammatory damage, there is evidence of genetic association between diabetes and histone deacetylases (HDACs); and HDAC inhibitors (HDACi) promote β-cell development, proliferation, differentiation and function and positively affect late diabetic microvascular complications. Here we review this evidence and propose that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes.

AB - Both common forms of diabetes have an inflammatory pathogenesis in which immune and metabolic factors converge on interleukin-1β as a key mediator of insulin resistance and β-cell failure. In addition to improving insulin resistance and preventing β-cell inflammatory damage, there is evidence of genetic association between diabetes and histone deacetylases (HDACs); and HDAC inhibitors (HDACi) promote β-cell development, proliferation, differentiation and function and positively affect late diabetic microvascular complications. Here we review this evidence and propose that there is a strong rationale for preclinical studies and clinical trials with the aim of testing the utility of HDACi as a novel therapy for diabetes.

U2 - 10.2119/molmed.2011.00021

DO - 10.2119/molmed.2011.00021

M3 - Journal article

C2 - 21274504

SN - 1076-1551

VL - 17

SP - 378

EP - 390

JO - Molecular Medicine

JF - Molecular Medicine

IS - 5-6

ER -

Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this